FIND and QuantuMDx partner to develop rapid genome-based diagnostics
4 November 2014
FIND, a Geneva-based non-profit organization, is joining
forces with UK diagnostics developer QuantuMDx Group to develop a
combined solution for the rapid detection of tuberculosis and
determination of drug resistance.
The time for full drug resistance profiling will be reduced from
a week to less than half an hour based on the molecular detection of
an extensive set of genetic markers by the simple handheld Q-POCTM
device developed by QuantuMDx.
The uniqueness of the nanowire technology developed by QuantuMDx
provides the potential to interrogate the bacterial genome with
unprecedented precision, as it allows not only targeted detection of
specific markers, but in addition (in a future evolution of the
present system) genetic sequencing on the same technology platform.
Under the partnership, FIND is supporting the development of an
appropriate and integrated sample handling compartment, while
QuantuMDx continues its platform development.
Catharina Boehme, FIND’s CEO noted that "after an extensive
screening of different Point-of-Care platform solutions amenable to
the decentralized testing for tuberculosis, we concluded that
QuantuMDx’s Q-POCTM system provides a unique set of capabilities
which allows for the seamless integration of future genetic
discoveries and hence will assure a long-term sustainability of the
molecular testing approach for tuberculosis."
Elaine Warburton, CEO of QuantuMDx said, “Our strategic
partnership with FIND is of immense importance to QuantuMDx. It not
only affords us a wealth of experience and expertise in developing
and commercializing a much-needed diagnostic device for developing
countries, but also provides independent validation of our strongly
held belief that the provision of low cost, truly point of care
molecular analysis for speciation and drug susceptibility status is
a practical and effective tool in helping support the early
identification and eventual eradication of MDR-TB and other
infectious disease humanitarian health challenges.”
Jonathan O’Halloran, QuantuMDx’s CSO and Q-POCTM inventor added,
"Excitingly, our partnership with FIND will support us in navigating
the complexities of commercializing a diagnostic device.
Furthermore, with networked Q-POCsTM deployed in the field
throughout the world we will have an early warning platform to
monitor novel pathogens and emerging hotspots of drug resistance in
real-time; a concept we like to call the Internet of Life."